Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Haba Laboratories Inc. (4925:JPX), powered by AI.
Haba Laboratories Inc. is currently trading at ¥1,710. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Haba Laboratories Inc. on Alpha Lenz.
Haba Laboratories Inc.'s P/E ratio is 11.2.
“Haba Laboratories Inc. trades at a P/E of 11.2 (undervalued) with modest ROE of 6.6%.”
Ask for details →Haba Laboratories Inc. is a notable entity within the cosmetics and skincare industry, focusing on producing high-quality beauty products primarily in Japan. The company's core mission centers around developing hypoallergenic skincare items that are both effective and gentle, ensuring broad consumer appeal among individuals with sensitive skin concerns. Haba Laboratories Inc. places a strong emphasis on using natural ingredients, avoiding additives or coloring agents, which aligns with the increasing global demand for eco-friendly and safe personal care products. Their product line includes a variety of facial cleansers, moisturizers, and anti-aging solutions, targeting a diverse demographic seeking reliable skincare regimes. As part of the broader cosmetics sector, Haba Laboratories Inc. plays a significant role in driving innovation and maintaining consumer trust. By leveraging research and development, the company continues to enhance its product offerings, contributing to the dynamic and competitive nature of the international beauty market. Its steadfast commitment to quality and sustainability ensures that it remains a key player, capitalizing on evolving consumer preferences towards clean and conscious beauty products.
“Haba Laboratories Inc. trades at a P/E of 11.2 (undervalued) with modest ROE of 6.6%.”
Ask for details →Haba Laboratories Inc. (ticker: 4925) is a company listed on JPX in the Consumer Defensive sector (Household & Personal Products). It has approximately 568 employees. Market cap is $6.5B.
The current price is 1,710 with a P/E ratio of 11.22x and P/B of 0.72x.
ROE is 6.61% and operating margin is 4.89%. Annual revenue is $12.1B.